Zoetis Inc. vs Axsome Therapeutics, Inc.: SG&A Expense Trends

SG&A Expense Trends: Zoetis Inc. vs Axsome Therapeutics, Inc.

In the ever-evolving pharmaceutical industry, understanding financial trends is crucial for investors and stakeholders. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent companies: Zoetis Inc. and Axsome Therapeutics, Inc., from 2014 to 2023.

A Decade of Financial Insights

Over the past decade, Zoetis Inc. has consistently maintained higher SG&A expenses, reflecting its expansive market operations. In 2023, Zoetis's SG&A expenses reached approximately $2.15 billion, marking a 31% increase from 2014. In contrast, Axsome Therapeutics, Inc. exhibited a dramatic rise in SG&A expenses, skyrocketing from a modest $1.39 million in 2014 to $323 million in 2023, a staggering increase of over 23,000%. This surge underscores Axsome's aggressive growth strategy and expanding market presence.

Conclusion

These trends highlight the contrasting growth trajectories and strategic priorities of these two pharmaceutical giants.